05.27.15
Richmond, Calif.-based Ekso Bionics Holdings Inc. has added Amy Wendell, former senior vice president, strategy and business development of Covidien, to its board of directors.
“At Covidien, Amy Wendell presided over an impressive acquisition strategy, acquiring more than 100 companies with leading-edge technologies across many healthcare sectors. She has combed through an incredible number of growth strategies and understands the ones that really make sense,” said Nathan Harding, Ekso CEO and co-founder. “We look forward to benefiting from Amy’s operational and product management experience as well as her strategic acumen.”
Since 1986, Wendell has served in a range of leadership positions at Covidien, formerly known as Tyco Healthcare/Kendall, where she led the company’s strategic planning and portfolio management functions, as well as all business development initiatives including mergers and acquisitions, integrations, equity investments, divestitures, licensing, distribution, and market intelligence. She received a bachelor’s degree from Lawrence Institute of Technology (Mich.) and a master’s degree in biomedical engineering from the University of Illinois.
“I have a long time interest in medical device technology and, perhaps even more, the process of guiding innovative companies to make a positive impact in people’s lives, hit business milestones and expand into new markets,” Wendell in prepared remarks. “I am excited by what Ekso Bionics has begun to accomplish and I am honored to be joining their board.”
Wendell’s appointment increases the size of Ekso Bionics’ board to seven.
Ekso Bionics makes robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company was founded in 2005.
“At Covidien, Amy Wendell presided over an impressive acquisition strategy, acquiring more than 100 companies with leading-edge technologies across many healthcare sectors. She has combed through an incredible number of growth strategies and understands the ones that really make sense,” said Nathan Harding, Ekso CEO and co-founder. “We look forward to benefiting from Amy’s operational and product management experience as well as her strategic acumen.”
Since 1986, Wendell has served in a range of leadership positions at Covidien, formerly known as Tyco Healthcare/Kendall, where she led the company’s strategic planning and portfolio management functions, as well as all business development initiatives including mergers and acquisitions, integrations, equity investments, divestitures, licensing, distribution, and market intelligence. She received a bachelor’s degree from Lawrence Institute of Technology (Mich.) and a master’s degree in biomedical engineering from the University of Illinois.
“I have a long time interest in medical device technology and, perhaps even more, the process of guiding innovative companies to make a positive impact in people’s lives, hit business milestones and expand into new markets,” Wendell in prepared remarks. “I am excited by what Ekso Bionics has begun to accomplish and I am honored to be joining their board.”
Wendell’s appointment increases the size of Ekso Bionics’ board to seven.
Ekso Bionics makes robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company was founded in 2005.